Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT05288062 | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | terminated | Phase 1 / Phase 2 | 57 | Jennifer AmengualOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02967276 | Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma(METDEXA-MM) | terminated | Phase 2 | 28 | University of Campinas, BrazilOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03757221 | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma(IDARA) | terminated | Phase 2 | 55 | University Hospital, CaenOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | terminated | Phase 2 | 46 | PfizerINDUSTRY | 2 | Apr 24, 2026 | clinicaltrials |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence(CPIT001) | terminated | Phase 1 / Phase 2 | 46 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01453088 | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older | terminated | Phase 2 | 63 | Hackensack Meridian HealthOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT05590377 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma(iinnovate-3) | terminated | Phase 1 / Phase 2 | 15 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 7 | Jan 30, 2026 | clinicaltrials |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | terminated | Phase 1 / Phase 2 | 272 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 16 | Jan 29, 2026 | clinicaltrials |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 146 | Novartis PharmaceuticalsINDUSTRY | 14 | Jan 13, 2026 | clinicaltrials |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma(CARTIFAN-1) | terminated | Phase 2 | 123 | Nanjing Legend Biotech Co.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 15 | Incyte CorporationINDUSTRY | 3 | Nov 4, 2025 | clinicaltrials |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma(LIMBER) | terminated | Phase 1 / Phase 2 | 22 | Incyte CorporationINDUSTRY | 3 | Oct 22, 2025 | clinicaltrials |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 23 | University of California, San DiegoOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT03376477 | Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission | terminated | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | terminated | Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | terminated | Phase 1 / Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 36 | Gilead SciencesINDUSTRY | 3 | May 2, 2025 | clinicaltrials |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 10 | University of Maryland, BaltimoreOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03871829 | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab | terminated | Phase 2 | 88 | Janssen Research & Development, LLCINDUSTRY | 13 | Mar 30, 2025 | clinicaltrials |
| NCT01997840 | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 103 | CelgeneINDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT03457142 | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy | terminated | Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 4 | GlaxoSmithKlineINDUSTRY | 2 | Mar 3, 2025 | clinicaltrials |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | terminated | Phase 2 | 1 | Hackensack Meridian HealthOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic(IFM2014-01) | terminated | Phase 2 | 26 | Intergroupe Francophone du MyelomeNETWORK | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04150965 | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | terminated | Phase 1 / Phase 2 | 14 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05117008 | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma(EMBRACE) | terminated | Phase 2 | 1 | Medical College of WisconsinOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 29 | Ichnos Sciences SAINDUSTRY | 3 | Jan 17, 2025 | clinicaltrials |
| NCT05191472 | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | terminated | Phase 2 | 3 | Alfred Chung, MDOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04816526 | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | terminated | Phase 2 | 13 | Cartesian TherapeuticsINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02002598 | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 23 | Suzanne Lentzsch, MDOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | terminated | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | terminated | Phase 2 | 17 | Emory UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Allogene TherapeuticsINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Altor BioScienceINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | terminated | Phase 2 | 5 | University of California, San FranciscoOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02661022 | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 9 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 105 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02700841 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | terminated | Phase 2 | 8 | University of NebraskaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 9 | GlaxoSmithKlineINDUSTRY | 3 | Mar 12, 2024 | clinicaltrials |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy | terminated | Phase 2 | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials